Inhibikase Therapeutics, Inc. (IKT)

1.65 +0.06 (+3.77%) USD  |  NASDAQ  |  Dec 24, 16:00
More

Inhibikase Therapeutics EV to Free Cash Flow

EV to Free Cash Flow Chart

View EV to Free Cash Flow for IKT.
Upgrade now.
Sep '18
Jan '19
May '19
 
285.00
270.00
255.00
240.00
View EV to Free Cash Flow Chart
Start Trial

Historical Data

View Historical Data
Start Trial

EV to Free Cash Flow Range, Past 5 Years

View EV to Free Cash Flow Range, Past 5 Years
Start Trial
--
Minimum
--
Maximum
--
Average
--
Median

EV to Free Cash Flow Benchmarks

View EV to Free Cash Flow Benchmarks
Start Trial
CEL-SCI Corp. Upgrade
AIM ImmunoTech, Inc. Upgrade
IGC Pharma, Inc. Upgrade
NovaBay Pharmaceuticals, Inc. Upgrade
Protalix Biotherapeutics, Inc. Upgrade

EV to Free Cash Flow Related Metrics

EV to CFO Upgrade
EV to Assets (Quarterly) Upgrade
EV to Earnings Upgrade